The Indian Pharma Industry under the Product Patent Regime |
ICMR HOME | Case Studies Collection
» Business Strategy Case Studies
Custom Search
Please note: This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source. Chat with us ![]() |
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract:
The note ends with an optimistic outlook stating that the Indian pharma industry will soon be an R&D hub for multinationals in custom research and clinical trials and the industry has the potential to tap the growing generics market in Europe and the US. Issues:
» Effect of multilateral trade agreements on an industry Contents:
Keywords:Indian Pharma Industry, Product patent, Process Patent, DPCO, FERA, Small Scale Industry, TRIPS, The Indian Patent Act, World Trade Organization, Exclusive Marketing Rights (EMR), Union Budget 2005-06, Wockhardt Ltd., Value Added Tax (VAT), Ranbaxy Laboratories Ltd., Dr. Reddy's Laboratories Limited, Patent Regime, Pharma Industry, Bulk Drugs, Pharmaceutical Industry, Exchange Regulated Act, Foreign Exchange, Domestic Market, Patent Act, Clinical Research, Leading Pharma Companies The Indian Pharma Industry under the Product Patent Regime - Next Page>> |
||||||||||||||||||||||||||||||||||||||||||||||||||
Case Studies Links:-
Case Studies,
Short Case Studies,
Simplified Case Studies.
Other Case Studies:-
Multimedia Case Studies,
Cases in Other Languages.
Business Reports Link:-
Business Reports.
Books:-
Textbooks,
Work Books,
Case Study Volumes.